Key points are not available for this paper at this time.
Increased eligibility for statin therapy impacts large proportions of the present population and healthcare budgets. Decisions to take and reimburse statins should be considered on the basis of expected cost-effectiveness and acceptability to patients.
Byrne et al. (Tue,) studied this question.